ZA953467B - Cyclopeptides of the formula I - Google Patents

Cyclopeptides of the formula I

Info

Publication number
ZA953467B
ZA953467B ZA953467A ZA953467A ZA953467B ZA 953467 B ZA953467 B ZA 953467B ZA 953467 A ZA953467 A ZA 953467A ZA 953467 A ZA953467 A ZA 953467A ZA 953467 B ZA953467 B ZA 953467B
Authority
ZA
South Africa
Prior art keywords
integrins
aminomethyl
leu
gly
beta
Prior art date
Application number
ZA953467A
Other languages
English (en)
Inventor
Alfred Jonczyk
Simon Goodman
Roland Haubner
Guenter Hoelzemann
Horst Kessler
Jochen Wermuth
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA953467B publication Critical patent/ZA953467B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/75Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/27Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA953467A 1994-04-30 1995-04-28 Cyclopeptides of the formula I ZA953467B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4415310A DE4415310A1 (de) 1994-04-30 1994-04-30 Cyclopeptide

Publications (1)

Publication Number Publication Date
ZA953467B true ZA953467B (en) 1996-01-17

Family

ID=6516993

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA953467A ZA953467B (en) 1994-04-30 1995-04-28 Cyclopeptides of the formula I

Country Status (21)

Country Link
US (1) US5693612A (xx)
EP (1) EP0683173B1 (xx)
JP (1) JP3711154B2 (xx)
KR (1) KR100360831B1 (xx)
CN (1) CN1161374C (xx)
AT (1) ATE183199T1 (xx)
AU (1) AU697614B2 (xx)
CA (1) CA2148194C (xx)
CZ (1) CZ286705B6 (xx)
DE (2) DE4415310A1 (xx)
DK (1) DK0683173T3 (xx)
ES (1) ES2137394T3 (xx)
GR (1) GR3031696T3 (xx)
HU (1) HU216795B (xx)
NO (1) NO311892B1 (xx)
PL (1) PL181272B1 (xx)
RU (1) RU2151776C1 (xx)
SK (1) SK281843B6 (xx)
TW (1) TW354790B (xx)
UA (1) UA46699C2 (xx)
ZA (1) ZA953467B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244622B2 (en) * 1996-04-03 2007-07-17 Applera Corporation Device and method for multiple analyte detection
DE19736772A1 (de) * 1997-08-23 1999-02-25 Merck Patent Gmbh Cyclopeptidderivate
JP2002533416A (ja) 1998-12-23 2002-10-08 ジー.ディー.サール & カンパニー 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−2インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
CN1507354A (zh) * 2001-03-02 2004-06-23 ͨ��ҽ�ƹ�˾ 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
AU2003213682C1 (en) * 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
US7371383B2 (en) * 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
CA2514653A1 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
EP2316487B1 (en) * 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
CN100429223C (zh) * 2004-02-06 2008-10-29 南京工业大学 环(d-苯丙-d-组)二肽的制备方法
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
ES2439390T3 (es) 2004-06-04 2014-01-22 The Scripps Research Institute Composiciones y procedimiento para el tratamiento de enfermedades neovasculares
JP2008516979A (ja) * 2004-10-14 2008-05-22 リゲル ファーマシューティカルズ インコーポレーティッド Ires仲介性翻訳の複素環式阻害剤およびその使用法
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
ATE490976T1 (de) * 2004-10-30 2010-12-15 Univ Pais Vasco B-lactam-rgd-cyclopeptide mit gamma-(g-)wendungen
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
DK2408802T3 (en) 2009-03-16 2017-08-28 Governing Council Univ Toronto CYCLIC AMINO ACID MOLECULES AND PROCEDURES FOR PREPARING IT
WO2017046416A1 (en) * 2015-09-18 2017-03-23 Technische Universität München LIGANDS FOR INTEGRIN AVß6, SYNTHESIS AND USES THEREOF
CA3004714A1 (en) 2015-11-11 2017-05-18 Encycle Therapeutics, Inc. Fragment synthesis of cyclic peptides
EP3538542B1 (en) 2016-11-11 2021-08-04 Zealand Pharma A/S Cyclic peptides multimers targeting alpha 4beta 7 integrin
EP3388445A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Peptide macrocycles and use thereof in the treatment of bacterial infections
US11286281B2 (en) 2017-05-10 2022-03-29 Zealand Pharma A/S Homodetic cyclic peptides targeting alpha-4-beta-7 integrin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472305A (en) * 1983-05-17 1984-09-18 Sterling Drug Inc. Hexapeptide amides
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
CA2106314A1 (en) * 1991-04-05 1992-10-06 John P. Burnier Platelet aggregation inhibitors having high specification for gpiibiiia
IL103252A (en) * 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UA43823C2 (uk) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren

Also Published As

Publication number Publication date
CN1161374C (zh) 2004-08-11
HUT75057A (en) 1997-03-28
KR950032275A (ko) 1995-12-20
KR100360831B1 (ko) 2003-01-24
HU216795B (hu) 1999-08-30
DE59506568D1 (de) 1999-09-16
EP0683173A1 (de) 1995-11-22
TW354790B (en) 1999-03-21
HU9501253D0 (en) 1995-06-28
AU697614B2 (en) 1998-10-15
GR3031696T3 (en) 2000-02-29
RU2151776C1 (ru) 2000-06-27
ATE183199T1 (de) 1999-08-15
JPH07304795A (ja) 1995-11-21
CZ107395A3 (en) 1995-11-15
UA46699C2 (uk) 2002-06-17
EP0683173B1 (de) 1999-08-11
ES2137394T3 (es) 1999-12-16
SK55895A3 (en) 1995-12-06
CZ286705B6 (en) 2000-06-14
CN1116628A (zh) 1996-02-14
NO951645L (no) 1995-10-31
DK0683173T3 (da) 2000-03-13
RU95106821A (ru) 1997-01-10
AU1772495A (en) 1995-11-09
CA2148194C (en) 2007-04-10
PL181272B1 (pl) 2001-07-31
PL308420A1 (en) 1995-11-13
NO311892B1 (no) 2002-02-11
DE4415310A1 (de) 1995-11-02
NO951645D0 (no) 1995-04-28
CA2148194A1 (en) 1995-10-31
US5693612A (en) 1997-12-02
JP3711154B2 (ja) 2005-10-26
SK281843B6 (sk) 2001-08-06

Similar Documents

Publication Publication Date Title
HUT75057A (en) Cyclopeptides
ATE410506T1 (de) Behandlung der pompeschen krankheit
ATE403677T1 (de) Beschleuniger des plättchenwachstums
ITMI922953A1 (it) Inibitori a doppia attivita&#39; biologica di no sintasi e cicloossigenasi procedimento per la loro preparazione e composizioni terapeutiche che li contengono.
IL112111A0 (en) Peptide derivatives and pharmaceutical compositions containing them
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
Cohen Synthetic and fermentation-derived angiotensin-converting enzyme inhibitors
TNSN87045A1 (fr) Procede de preparation d&#39;inhibiteurs de l&#39;enzyme de conversion de l&#39;angiotensine
AR002245A1 (es) Antagonistas del receptor de adhesion, procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos parapreparar medicamentos.
CA2279184A1 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
FI961634A0 (fi) Antitromboottisia atsasykloalkyylialkanoyyli peptidejä ja pseudopeptidejä
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69420574T2 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
RU97112901A (ru) Тромболитические средства
ATE49958T1 (de) Pharmazeutische zusammensetzungen mit immunodepressivwirkung.
MX9601659A (es) Antagonistas del receptor de adhesion, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades.